Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study
Launched by HOSPICES CIVILS DE LYON · Dec 9, 2019
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The COGRare5 Study is a research trial focused on understanding how rare vascular diseases can affect pregnancies. These conditions, such as Osler Rendu Disease and Marfan Syndrome, can lead to serious health issues for both mothers and their babies. The goal of this study is to learn more about potential pregnancy complications in women with these rare diseases so that doctors can improve care, reduce risks, and ultimately save lives.
To participate in this study, women between the ages of 18 and 45 who are currently pregnant or have given birth in the last month may be eligible. Participants will need to have a diagnosis of a rare vascular disease confirmed through medical tests. Those who join the study will help researchers gather important information that could lead to better guidelines for managing pregnancies in women with these conditions. It’s important to note that the study is actively recruiting participants, and women who meet the criteria are encouraged to consider joining.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women aged ≥ 18 years and ≤45 years at the time of inclusion
- • Pregnant and/or having given birth less than 1 month (≤ 30 days)
- • Clinically and/or radiological and/or molecular biology diagnosis of a rare vascular disease before or during pregnancy or one month after delivery.
- • Having been informed of all pertinent aspects of the study and provided oral non-opposition.
- Exclusion Criteria:
- • Any person not fulfilling the inclusion criteria or refusing to take part in the study.
- • Major under legal protection
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Dijon, , France
Angers, , France
Bordeaux, , France
Boulogne Billancourt, , France
Bron, , France
Bron, , France
Bron, , France
Caen, , France
Clermont Ferrand, , France
Lille, , France
Lille, , France
Montpellier, , France
Nancy, , France
Nice, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Poitiers, , France
Rennes, , France
Rennes, , France
Rouen, , France
Saint Herblain, , France
Saint étienne, , France
Strasbourg, , France
Suresnes, , France
Toulouse, , France
Toulouse, , France
Tours, , France
Vandœuvre Lès Nancy, , France
Bron, , France
Nantes, , France
Nice, , France
Strasbourg, , France
Strasbourg, , France
Tours, , France
Patients applied
Trial Officials
Sophie DUPUIS-GIROD, MD
Principal Investigator
Service de Génétique - Hôpital Femme-Mère-Enfant - HCL
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials